Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Status Epilepticus | 2 | 2018 | 36 | 0.690 |
Why?
|
| Epilepsy, Absence | 2 | 2018 | 11 | 0.690 |
Why?
|
| Seizures | 3 | 2021 | 198 | 0.620 |
Why?
|
| Immunosuppressive Agents | 2 | 2017 | 227 | 0.620 |
Why?
|
| Diffuse Cerebral Sclerosis of Schilder | 1 | 2018 | 8 | 0.600 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2018 | 6 | 0.600 |
Why?
|
| Myoclonus | 1 | 2018 | 9 | 0.580 |
Why?
|
| Mitochondrial Diseases | 1 | 2018 | 41 | 0.580 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2017 | 45 | 0.550 |
Why?
|
| Methotrexate | 1 | 2017 | 76 | 0.550 |
Why?
|
| Epilepsy | 2 | 2021 | 181 | 0.540 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 82 | 0.530 |
Why?
|
| Neuromyelitis Optica | 1 | 2016 | 5 | 0.530 |
Why?
|
| Nerve Tissue Proteins | 1 | 2018 | 191 | 0.510 |
Why?
|
| Erythema Infectiosum | 1 | 2015 | 3 | 0.510 |
Why?
|
| Parvovirus B19, Human | 1 | 2015 | 17 | 0.500 |
Why?
|
| Bone Diseases, Developmental | 1 | 2014 | 14 | 0.470 |
Why?
|
| Complementary Therapies | 1 | 2015 | 26 | 0.470 |
Why?
|
| Tooth Abnormalities | 1 | 2014 | 12 | 0.470 |
Why?
|
| Drug Resistance | 1 | 2015 | 65 | 0.460 |
Why?
|
| Repressor Proteins | 1 | 2014 | 149 | 0.430 |
Why?
|
| Intellectual Disability | 1 | 2014 | 121 | 0.420 |
Why?
|
| Abnormalities, Multiple | 1 | 2014 | 166 | 0.420 |
Why?
|
| Stroke | 1 | 2017 | 495 | 0.400 |
Why?
|
| Mutation | 1 | 2014 | 1275 | 0.310 |
Why?
|
| Electroencephalography | 4 | 2018 | 304 | 0.280 |
Why?
|
| Child | 6 | 2018 | 6931 | 0.240 |
Why?
|
| Adolescent | 4 | 2019 | 6453 | 0.210 |
Why?
|
| Humans | 13 | 2021 | 50419 | 0.190 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2019 | 8 | 0.170 |
Why?
|
| Oximetry | 1 | 2020 | 67 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 1546 | 0.160 |
Why?
|
| Cerebrovascular Circulation | 1 | 2020 | 132 | 0.160 |
Why?
|
| Multiple Sclerosis | 1 | 2019 | 64 | 0.160 |
Why?
|
| Frameshift Mutation | 1 | 2018 | 16 | 0.150 |
Why?
|
| Female | 5 | 2020 | 27053 | 0.140 |
Why?
|
| Syndrome | 1 | 2018 | 236 | 0.140 |
Why?
|
| Developmental Disabilities | 2 | 2015 | 119 | 0.130 |
Why?
|
| Plasmapheresis | 1 | 2016 | 11 | 0.130 |
Why?
|
| Azathioprine | 1 | 2016 | 10 | 0.130 |
Why?
|
| Prednisolone | 1 | 2016 | 54 | 0.130 |
Why?
|
| Hemispherectomy | 1 | 2015 | 11 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 2016 | 113 | 0.120 |
Why?
|
| Cerebral Palsy | 1 | 2015 | 37 | 0.120 |
Why?
|
| Brain Waves | 1 | 2014 | 16 | 0.120 |
Why?
|
| Facies | 1 | 2014 | 33 | 0.120 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2014 | 9 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 640 | 0.110 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2014 | 12 | 0.110 |
Why?
|
| Glucocorticoids | 1 | 2016 | 233 | 0.110 |
Why?
|
| Benzodiazepines | 1 | 2014 | 70 | 0.110 |
Why?
|
| Spasms, Infantile | 1 | 2014 | 29 | 0.110 |
Why?
|
| Male | 7 | 2020 | 25866 | 0.110 |
Why?
|
| Sleep | 1 | 2014 | 183 | 0.110 |
Why?
|
| Anticonvulsants | 1 | 2014 | 125 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1029 | 0.100 |
Why?
|
| Flavoproteins | 1 | 2019 | 5 | 0.040 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2019 | 20 | 0.040 |
Why?
|
| Pedigree | 1 | 2019 | 119 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 2019 | 75 | 0.040 |
Why?
|
| Age of Onset | 1 | 2019 | 109 | 0.040 |
Why?
|
| Steroids | 1 | 2019 | 57 | 0.040 |
Why?
|
| Infant | 2 | 2020 | 3648 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 165 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 825 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 489 | 0.030 |
Why?
|
| Quality of Life | 1 | 2021 | 850 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2014 | 103 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 3953 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2020 | 6274 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2015 | 5265 | 0.010 |
Why?
|